Simmitecan
Simmitecan is a potent topoisomerase I (TOP1) inhibitor, which is a 9-substituted lipophilic camptothecin (Camptothecin (HY-16560)) derivative. Simmitecan blocks DNA replication and transcription, thereby inducing tumor cell apoptosis by inhibiting the activity of TOP1. Simmitecan can be used in the research of cancers such as liver cancer.
For research use only. We do not sell to patients.
- CAS No.: 951290-31-6
- Formula: C34H38N4O6
- Molecular Weight:598.70
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Topoisomerase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Top1 |
CYP3A4 8.95 μM (IC50) |
CYP2D6 32.9 μM (IC50) |
In Vitro
Simmitecan moderately inhibits the activity of CYP3A4 and weakly inhibits the activity of CYP2D6 in an in vitro recombinant human cytochrome P450 enzyme system, with IC50 values of 8.95 μM and 32.9 μM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | Cmax | AUC0-24 | T1/2 | MRT | CLplasma | Vss |
|---|---|---|---|---|---|---|---|---|
| Mice[1] | 15 mg/kg | i.v. | 5124 nM | 8142 nM·h | 0.95 h | 1.14 h | 3.16 L/h/kg | 3.57 L/kg |
| Rat[1] | 3.75 mg/kg | i.v. | 1651 nM | 3709 nM·h | 1.45 h | 1.85 h | 1.82 L/h/kg | 3.34 L/kg |
| Rat[1] | 7.5 mg/kg | i.v. | 3518 nM | 8922 nM·h | 1.46 h | 1.92 h | 1.54 L/h/kg | 2.91 L/kg |
| Rat[1] | 15 mg/kg | i.v. | 7192 nM | 17906 nM·h | 1.42 h | 1.91 h | 1.51 L/h/kg | 2.86 L/kg |
| Dog[1] | 1.25 mg/kg | i.v. | 616 nM | 2050 nM·h | 1.95 h | 2.74 h | 1.12 L/h/kg | 3.03 L/kg |
| Dog[1] | 2.5 mg/kg | i.v. | 1135 nM | 3712 nM·h | 1.90 h | 2.74 h | 1.20 L/h/kg | 3.27 L/kg |
| Dog[1] | 5 mg/kg | i.v. | 2101 nM | 6417 nM·h | 1.72 h | 2.45 h | 1.46 L/h/kg | 3.54 L/kg |
In Vivo
Simmitecan (15 mg/kg; intravenous injection; single administration; 8 h) exhibits extensive distribution in tissues including tumors and substantial conversion into its active metabolite L-2-Z in nude mouse xenograft models bearing the human hepatocellular carcinoma SMMC-7721 cell line[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male and female, 250-300 g)[1]
-
Dosage:3.75 mg/kg; 7.5 mg/kg; 15 mg/kg
-
Administration:i.v.; single dose; 48 h
-
Result:Was rapidly biotransformed into its active metabolite L-2-Z in vivo and extensively distributed in most tissues (with the highest concentrations observed in the pancreas, kidneys, and liver).
Was predominantly eliminated via biliary excretion, and metabolism was also a major elimination route for the intact drug after iv administration.
-
Animal Model:Nude (male and female, 18-20 g, xenograft model of human hepatic cancer SMMC-7721 cells)[1]
-
Dosage:15 mg/kg
-
Administration:i.v.; single dose; samples harvested at 0.25, 1, 2, 4, 8 h
-
Result:Simmitecan and its active metabolite L-2-Z rapidly distributed to tissues, reaching peak concentrations 15 minutes after dosing.
Chemical Information
-
CAS No. 951290-31-6
-
Molecular Weight 598.70
-
Formula C34H38N4O6
-
SMILES
O=C1N2C(C=3C(C2)=CC=4C(N3)=CC=C(OC(=O)N5CCC(CC5)N6CCCCC6)C4CC=C)=CC7=C1COC(=O)[C@@]7(CC)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
Purity & Documentation
References
[1]. Hu ZY, et al. Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals. Acta pharmacologica Sinica. 2013 Nov;34(11):1437-48. [Content Brief]
[2]. Zhou J, et al. A validated HPLC-MS/MS method for determination of simmitecan and its metabolite chimmitecan in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor. Journal of separation science. 2021 Nov;44(21):3959-3966. [Content Brief]
[3]. Zhang Q, et al. A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor. Frontiers in pharmacology. 2022;13:833583. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)